7,562.50

-12.00

-0.16%

51,916.00

-217.00

-0.42%

28,122.75

-4.75

-0.02%

Russell 2000 Futures

2,813.70

-4.10

-0.15%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,933.90

-35.70

-0.90%

76,576.91

-1,672.06

-2.14%

Crude Oil Dec 26

97.22

+0.76

+0.79%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCQX - Delayed Quote USD

Roche Holding AG (RHHBY)

60.68 -0.62 (-1.01%)

At close: November 2 at 3:59:59 PM EST

Loading Chart for RHHBY

Chart Range Bar

Interval:

In partnership with ChartIQ

Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens

Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens

RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines

RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines

SIG vs. CFRUY: Which Stock Is the Better Value Option?

SIG vs. CFRUY: Which Stock Is the Better Value Option?

Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive Disruption

Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive Disruption

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

UBS sees Roche giredestrant potential priced in after 50% share rally

UBS sees Roche giredestrant potential priced in after 50% share rally

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

Roche Holding (SWX:ROP) Expands ADC Pipeline As Late Stage Trial Results Impress

Roche Holding (SWX:ROP) Expands ADC Pipeline As Late Stage Trial Results Impress

Roche, In A Buy Zone, Leans On Diagnostics To Overcome Light Drug Sales

Roche, In A Buy Zone, Leans On Diagnostics To Overcome Light Drug Sales

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

Mobilize your Website

View Site in Mobile | Classic

Share by: